Eli Lilly's Mounjaro (Tirzepatide) has emerged as a breakthrough in addressing two significant health challenges: type 2 diabetes and obesity. By mimicking the action of two critical hormones, GLP-1 and GIP, Mounjaro effectively regulates blood sugar levels while suppressing appetite, leading to notable weight-loss outcomes. Its efficacy has been backed by clinical trials, making it a promising contender among weight-loss medications in India. However, its pricing INR 3,500 for a 2.5 mg vial and INR 4,375 for a 5 mg vial poses accessibility concerns, especially in a cost-sensitive market like India.

Considering the significance of this topic, SPER Market Research has conducted an in-depth research study across 95 Diabetologists and Endocrinologists to understand their perceptions and sentiments associated with this brand. The insights from this study will be valuable in shaping discussions and strategies around the event.

Despite the pricing challenges, Mounjaro has garnered positive feedback from diabetologists and endocrinologists. With 79% of specialists "very likely" to prescribe it, their optimism stems from the drug's dual-action mechanism, significant A1c reductions, and its potential cardioprotective benefits. However, cautious perspectives also persist due to side effects like nausea and vomiting and the lack of long-term safety data specific to the Indian population. These factors contribute to a balanced yet hopeful sentiment regarding its adoption for chronic weight management and diabetes control.

When compared to competitors such as Wegovy and Ozempic, Mounjaro stands out with its superior clinical data and additional health benefits. While Wegovy is focused purely on GLP-1 agonism, and Ozempic is designed primarily for diabetes management, Mounjaro's dual mechanism offers a more comprehensive approach. That said, its high cost and limited real-world data may hinder its market penetration. As India tackles a growing obesity epidemic, innovative treatments like Mounjaro could play a pivotal role provided cost and safety concerns are addressed in the future.